UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 403

Sortiert nach

Postmerger Gravitational-Wave Signatures of Phase Transitions in Binary Mergers

Physical review letters, 2020-05, Vol.124 (17), p.171103-171103, Article 171103

2020

Volltextzugriff (PDF)

Signatures of Quark-Hadron Phase Transitions in General-Relativistic Neutron-Star Mergers

Physical review letters, 2019-02, Vol.122 (6), p.061101-061101, Article 061101

2019

Volltextzugriff (PDF)

On the deconfinement phase transition in neutron-star mergers

The European physical journal. A, Hadrons and nuclei, 2020-02, Vol.56 (2), Article 59

2020

Volltextzugriff (PDF)

Viscous Dissipation and Heat Conduction in Binary Neutron-Star Mergers

Physical review letters, 2018-01, Vol.120 (4), p.041101-041101, Article 041101

2018

Volltextzugriff (PDF)

Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors

The oncologist (Dayton, Ohio), 2001-08, Vol.6 (4), p.363-373

2001

Volltextzugriff (PDF)

Rotational properties of hypermassive neutron stars from binary mergers

Physical review. D, 2017-08, Vol.96 (4), p.043004, Article 043004

2017

Volltextzugriff (PDF)

Constraining twin stars with GW170817

Physical review. D, 2019-05, Vol.99 (10), p.103009, Article 103009

2019

Volltextzugriff (PDF)

Reproducibility of Metabolic Measurements in Malignant Tumors Using FDG PET

The Journal of nuclear medicine (1978), 1999-11, Vol.40 (11), p.1771-1777

1999

Volltextzugriff (PDF)

The tumor neomatrix component fibrillin-1 (FBN1) is a druggable oncologically relevant target: Proof-of-principle in vitro using an FDA-approved medicine as pioneer inhibitor of protein hydroxylation (274)

Gynecologic oncology, 2022-08, Vol.166, p.S146

2022

Volltextzugriff (PDF)

The immune checkpoint controller C1q (C1QA/B/C) is a druggable oncologically relevant target: Proof-of-concept in vitro with an FDA-approved medicine, used as pioneer inhibitor of protein hydroxylation (273)

Gynecologic oncology, 2022-08, Vol.166, p.S145-S146

2022

Volltextzugriff (PDF)

Drug-induced reactivation of apoptosis abrogates HIV-1 infection

PloS one, 2013-09, Vol.8 (9), p.e74414-e74414

2013

Volltextzugriff (PDF)

411 Cancer cell stemness and collagen regulators of stemness in uterine serous carcinoma (USC) mirror ovarian serous cancer (OSC) cell stemness: evidence emerging from ARK1-USC

International journal of gynecological cancer, 2020-12, Vol.30 (Suppl 4), p.A41-A41

2020

Volltextzugriff (PDF)

Blocking eIF5A Modification in Cervical Cancer Cells Alters the Expression of Cancer-Related Genes and Suppresses Cell Proliferation

Cancer research (Chicago, Ill.), 2014-01, Vol.74 (2), p.552-562

2014

Volltextzugriff (PDF)

Abstract 2030: Oncological relevance of protein hydroxylase inhibitors (PHI): results of testing an emerging concept with an orally active pioneer medicine that blocks the hydroxylations of proline and lysine residues

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2030-2030

2021

Volltextzugriff (PDF)

Matrix recruitment by malignant cells (MRMC) in uterine serous carcinoma (USC)-derived ARK1 identifies the procurement of vessel wall components (VWCs) as novel therapeutic target

Gynecologic oncology, 2021-08, Vol.162, p.S204-S204

2021

Volltextzugriff (PDF)

Canonical transformation path to gauge theories of gravity

Physical review. D, 2017-06, Vol.95 (12), Article 124048

2017

Volltextzugriff (PDF)

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study

Annals of oncology, 2010-11, Vol.21 (11), p.2233-2239

2010

Volltextzugriff (PDF)

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor

Investigational new drugs, 2008-02, Vol.26 (1), p.45-51

2008

Volltextzugriff (PDF)

Genome-directed identification of novel, immediately druggable targets in uterine serous papillary carcinoma (USPC)

Gynecologic oncology, 2020-10, Vol.159, p.326-326

2020

Volltextzugriff (PDF)

Novel, immediately druggable targets in the ARK1 model of uterine serous papillary carcinoma (USPC): Proof-of-principle and clinical implications of blocking oncologically relevant posttranslational hydroxylations with a pioneer drug

Gynecologic oncology, 2020-10, Vol.159, p.329-329

2020

Volltextzugriff (PDF)

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Journal of clinical oncology, 2009-10, Vol.27 (28), p.4787-4792

2009

Volltextzugriff (PDF)

Neutron star mergers in the context of the hadron–quark phase transition

Journal of astrophysics and astronomy, 2018-08, Vol.39 (4), p.1-11, Article 45

2018

Volltextzugriff (PDF)

Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer

Annals of oncology, 2009-09, Vol.20 (9), p.1565-1575

2009

Volltextzugriff (PDF)

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

Journal of clinical oncology, 2004-06, Vol.22 (12), p.2336-2347

2004

Volltextzugriff (PDF)

1 – 25 von 403

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(362)
Mit Volltextzugriff
(358)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(188)
Humans
(167)
Life Sciences & Biomedicine
(149)
Biological And Medical Sciences
(113)
Oncology
(107)
Medical Sciences
(95)
Female
(85)
Pharmacology. Drug Treatments
(76)
Male
(71)
Antineoplastic Agents
(68)
Middle Aged
(68)
Chemotherapy
(64)
Adult
(59)
Aged
(59)
Neoplasms - Drug Therapy
(47)
Pharmacology & Pharmacy
(39)
Physical Sciences
(35)
Antineoplastic Agents - Therapeutic Use
(32)
Animals
(31)
Dose-Response Relationship, Drug
(31)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

European Journal Of Cancer
(37)
Investigational New Drugs
(29)
Journal Of Clinical Oncology
(25)
Annals Of Oncology
(18)
Anti-Cancer Drugs
(14)
Seminars In Oncology
(14)
Cancer Research
(12)
Pediatric Research
(11)
Febs Letters
(10)
Journal Of Pediatric Gastroenterology And Nutrition
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Postmerger Gravitational-Wave Signatures of Phase Transitions in Binary Mergers

Signatures of Quark-Hadron Phase Transitions in General-Relativistic Neutron-Star Mergers

On the deconfinement phase transition in neutron-star mergers

Viscous Dissipation and Heat Conduction in Binary Neutron-Star Mergers

Pemetrexed Disodium: A Novel Antifolate Clinically Active Against Multiple Solid Tumors

Rotational properties of hypermassive neutron stars from binary mergers

Clinical development of new drug-radiotherapy combinations

Constraining twin stars with GW170817

Reproducibility of Metabolic Measurements in Malignant Tumors Using FDG PET

The tumor neomatrix component fibrillin-1 (FBN1) is a druggable oncologically relevant target: Proof-of-principle in vitro using an FDA-approved medicine as pioneer inhibitor of protein hydroxylation (274)

The immune checkpoint controller C1q (C1QA/B/C) is a druggable oncologically relevant target: Proof-of-concept in vitro with an FDA-approved medicine, used as pioneer inhibitor of protein hydroxylation (273)

Drug-induced reactivation of apoptosis abrogates HIV-1 infection

411 Cancer cell stemness and collagen regulators of stemness in uterine serous carcinoma (USC) mirror ovarian serous cancer (OSC) cell stemness: evidence emerging from ARK1-USC

Blocking eIF5A Modification in Cervical Cancer Cells Alters the Expression of Cancer-Related Genes and Suppresses Cell Proliferation

Abstract 2030: Oncological relevance of protein hydroxylase inhibitors (PHI): results of testing an emerging concept with an orally active pioneer medicine that blocks the hydroxylations of proline and lysine residues

Matrix recruitment by malignant cells (MRMC) in uterine serous carcinoma (USC)-derived ARK1 identifies the procurement of vessel wall components (VWCs) as novel therapeutic target

Canonical transformation path to gauge theories of gravity

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study

The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor

Genome-directed identification of novel, immediately druggable targets in uterine serous papillary carcinoma (USPC)

Novel, immediately druggable targets in the ARK1 model of uterine serous papillary carcinoma (USPC): Proof-of-principle and clinical implications of blocking oncologically relevant posttranslational hydroxylations with a pioneer drug

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

Neutron star mergers in the context of the hadron–quark phase transition

Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer

Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

Suchergebnisse filtern